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Does response shift bias invalidate asking patients if they
are better or worse?When assessing the success of treatments, clinicians ask
patients whether and by how much the patient is better or
worse than before therapy was started (ie, ‘‘Since xx, has
your condition changed, and if so, by how much?’’). Many
trials do include such transition questions, but there is a de-
bate as to their accuracy. The debate centers around the
extent to which there is a ‘response shift’ caused by the pa-
tient changing their recollection and interpretation of the
‘before’ assessment by the time of the ‘after’ assessment.
This has led the FDA to rarely accept ‘transition change’
scores (eg, how much has your pain/quality of life im-
proved since the beginning of the trial?) in pivotal trials,
preferring to subtract the ‘before’ absolute status (eg, how
is your pain/quality of life today?) assessed at the beginning
of the study from the same absolute (eg, how is your health/
quality of life today?).
Response shift is defined as ‘‘a change in the meaning of
one’s self-evaluation of a target construct as a result of 1) a
change in the respondent’s internal standards of measure-
ment (ie, scale recalibration); 2) a change in the respondent’s
values (ie, the importance of component domains constitut-
ing the target construct; ie, reprioritization), or 3) a redefini-
tion of the target construct (ie, reconceptualization).’’
Barclay and Tate examine the first 2 of these (recalibration
and reprioritization) in a cohort of older men with and with-
out stroke. Recalibration of physical function occurred in
both groups. Reprioritization of role limitations because of
physical health occurred in the stroke-free groups. In another
article, Grovle et al. show that a transition index consisting
of patient ratings of global perceived change over the past
2 years were strongly influenced by the current health status.
In contrast to the above concerns, there is anecdotal evidence
from arthritis and multiple sclerosis trials that patients can
detect and report change before the absolute measure dem-
onstrates this. The JCE has invited an article series from
some thought leaders in this area to investigate whether
and when such ‘transition change questions’ are valid.
Two other articles address methodological issues of
patient-reported outcomes. Patient-reported outcomes are
the focus of the PROMIS program, which is now producing
different item banks. In this issue, Rose et al. present details
of the development and some psychometric properties of
the Physical Function item bank. This item bank consists
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Open access under CC BY-NC-ND license.extremity functions and instrumental activities of daily liv-
ing; we still await a direct comparison with the existing
legacy instruments in trials of interventions to establish
their ability to reduce the sample size requirement in new
clinical trials. Patient satisfaction is an important compo-
nent of patient-reported outcomes and quality assurance.
Hawthorne et al. challenge the traditional models of patient
satisfaction developed in the 1980s and instead have adop-
ted a newer framework of 7 components (Appropriate ac-
cess, provision of health information, empathy with the
patient, participation in making choices, satisfaction with
the treatment provided, effectiveness of treatment [includ-
ing the extent to which treatment meets patient expectations
of care and helps the patient in their daily life], and general
satisfaction). They have developed and begun to establish
the psychometric properties of a new generic, short, valid,
and reliable measure of patient satisfaction, the Short As-
sessment of Patient Satisfaction (SAPS) scale.
Four articles in this issue address systematic review
methods. Conventional diagnostic test accuracy (DTA)
meta-analyses have the potential to provide summary esti-
mates that are highly improbable for a particular target set-
ting. Willis and Hyde propose a tailoring approach to
address this by use of routine data from practice to define
an ‘‘applicable region’’ for studies in receiver operating
characteristic space. After qualitative appraisal, studies are
selected based on the probability that their study accuracy
estimates arose from parameters lying in this applicable re-
gion. This is applied to the example of the Pap test in the
UK NHS Cervical Screening Programme.
Systematic reviews often exclude non-English language
articles from their analyses, and there is evidence to suggest
that English-language bias may reduce the pooled treatment
effect size and produce less precise estimates of effect. How-
ever, study teams conducting systematic reviews may find
it challenging to locate sufficient teams of foreign-language
reviewers to include non-English language. Busse et al. pro-
pose use of a simple 3-step rule (excluding languageswith less
than 3 articles, reviewing titles and abstracts for clear indica-
tions of eligibility, and noting the lack of a clearly reported
statistical analysis [unless the word ‘‘random’’ appears]); this
led to accurate classification of 51 of 53 articles.
As attested to in past JCE articles, consensus is hard
to achieve on searching strategies in general and in
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and enormous numbers of citations are found in MEDLINE
because of vague searching terms [1,2]; Cooper et al. report
on a new population search filter for hard-to-reach popula-
tions. This filter increased search efficiency by reducing the
number of references by 65% for a systematic review in or-
der to capture all relevant populations (eg, homeless people,
immigrants, substance misusers) in a public health system-
atic review. These authors tested the filter in a Medline case
study to inform guidance in the UK on identifying and
managing tuberculosis among hard-to-reach groups.
The impact of missing participant data in trials and meta-
analyses of trials is always of concern if there is the possibil-
ity that in positive trials (ie, those with a claimed significant
treatment effect) in the intervention group, the outcomes of
participants with missing data are worse than the outcomes
of those with available data. The traditional way of handling
this is to assume that all dropouts in the experimental group
had bad outcomes and those in the control group had good
outcomes; this is often not plausible. Therefore, Ebrahim
et al., in a previous paper in JCE, have proposed a process
of a complete-case analysis as the primary meta-analysis
and applying 4 progressively more stringent imputation
strategies as sensitivity analyses to assess the risk of bias as-
sociated with missing participant data. The previous paper
showed how to apply this to meta-analyses using continuous
data with the same instrument [3]. The paper in this issue
does the same with examples for continuous data measured
with different instruments.
The remaining articles cover a number of different
topics. The genetic epidemiology community has agreed
on the GRIPS criteria for scientific reporting of Genetic
RIsk Prediction Studies. In this issue, Iglesias et al. estab-
lish the baseline for these criteria by showing that in
2010 only 10% of these studies reported all essential items
needed to perform external validation of the risk model. In-
itiatives are now being developed to improve the compli-
ance with these criteria.
The Framingham Risk Score was a landmark in epi-
demiology, but may now be outdated given the change in
population demographics and the absence of important
new items, items, such as absence of waist circumference
and triglycerides, in the index. In this issue, Tzoulaki
et al. show that, notwithstanding the above, it has been
widely used for purposes for which it was not intended,
such as in a variety of different populations to predict a
range of outcomes [4,5]. The predictive performance in
these settings is unknown and non-validated, and the con-
clusions drawn from these studies may well not be valid.
Record linkage is increasingly important as we move in-
to the era of Big Data [6]. Cromwell et al. report on a ‘look-
back’ technique that proved useful to solve problems of
missing data of a simple item: that of parity, when review-
ing maternity outcomes in the UK. This led one study to ex-
clude 76 of 146 English NHS trusts because parity was
missing from more than 50% of their deliveries in at least7 of the 9 years analyzed. This was adequately solved using
this look- back technique on over 350,000 births.
JCE has published a number of articles on comorbidity
indices and, in this issue, Sarfati et al. report on a large der-
ivation and validation cohort to develop a new administra-
tive database based comorbidity index for a range of cancer
types. This performed better than the Charlson Index for
some cancer types but not others.
The Tempo effect is a newly recognized problem in the
interpretation of life expectancy not previously appreciated
in the public health literature, although known to the de-
mography community. Peters et al. demonstrate this using
the example of the likely falsely optimistic increased esti-
mate of the change in life expectancy after the unification
of East and West Germany. This example is used to demon-
strate that this effect can be as large as 10 years.
A myriad of methods are used in the most common soft-
ware packages to calculate sample size requirements for the
difference between two proportions; these are dependent on
the choice of sample size formula and software. Bell et al.
used 4 sample size formulae to calculate sample size for 9
scenarios. Software documentation for SAS, Stata,
G*Power, PASS, StatXact, and several R libraries were
searched for default assumptions. Each package was used
to calculate sample size for 2 scenarios. Sample size varied
as much as 60% depending on the formula used. This was
due to variation in the sample size formulae and the default
settings implemented in multiple statistical software. Better
documentation of the sample size formulae and default set-
tings is required in many statistical software packages.
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